China Aiming To Slash Certain Cancer Drug Prices To Ease Access
This article was originally published in PharmAsia News
Amid calls to expand access to costly patented cancer drugs, China is negotiating with several suppliers for the potential inclusion of selected targeted therapies in national reimbursement schemes. But could the potential benefits justify the likely 50% cuts?
Register for our free email digests: